Welcome to our dedicated page for Establishment Labs Holdings news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Holdings stock.
Establishment Labs Holdings Inc. (ESTA) is a leading global medical technology company, renowned for its innovation in the field of medical devices and aesthetics. Specializing in advanced silicone-filled breast and body shaping implants, the company has over 30 years of experience in breast implant manufacturing. Establishment Labs designs, develops, manufactures, and markets an extensive product portfolio that ensures safety and meets the current needs and preferences of plastic surgeons and patients.
Known for its flagship product, Motiva Implants®, Establishment Labs has set a benchmark in the industry for product innovation and safety. The company operates in multiple geographical segments, including Europe, Latin America, Asia-Pacific/Middle East, and other regions. Establishment Labs' products are distributed to medical distributors, physicians, hospitals, and clinics through direct sales channels.
Recent achievements include the continued global expansion of the Motiva Implants® brand and strategic partnerships aimed at advancing medical and aesthetic technology. With a strong focus on the future, the company is dedicated to pushing the boundaries of innovation and safety in medical devices.
Establishment Labs maintains a robust financial condition, driven by its commitment to quality and continuous improvement. The company’s ongoing projects include research and development initiatives aimed at introducing new and improved products that align with market demands.
For the latest updates and relevant information about Establishment Labs Holdings Inc., stay tuned to this page for the most recent news and developments.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced its participation in The Aesthetic Meeting 2022 from April 20-24 in San Diego, California. Dr. Caroline Glicksman will present an update on the Motiva US Core Clinical Study on April 21 at 3:50pm PT. The company will also host an event honoring Dr. Brian Kinney's contributions to plastic surgery and women's health. Established in 2010, Establishment Labs specializes in breast aesthetics and reconstruction, delivering approximately 2.0 million Motiva Implants in over 80 countries.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a leader in women's health technology, announced that CEO Juan José Chacón-Quirós and CFO Raj Denhoy will present at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 2:10 PM Eastern Time. A live webcast of the presentation can be accessed on the Establishment Labs investor relations website, with an archived version available afterward. The company specializes in breast aesthetics, offering Motiva Implants® and related products that have been delivered to over 80 countries.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported fourth-quarter 2021 revenue of $35.3 million, up 31% year-over-year, achieving a new quarterly record. The full-year revenue totaled $126.7 million, a 50% increase. Fourth-quarter gross profit was 68.6% of revenue, significantly higher than 54.3%% in 2020. For 2022, the company projects revenue of $155 million to $165 million, reflecting a 22% to 30% growth. However, operating expenses increased by 48.2% to $33.6 million.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has achieved a significant milestone by surpassing two million Motiva Implants in the market. This achievement reflects a steady growth trajectory, with the company delivering one million implants in the first seven years and doubling that in just two years. The implants maintain an impressive less than 1% clinical complication rate, showcasing their safety and effectiveness. Operating in over 80 countries, Establishment Labs is committed to innovation in breast aesthetics and reconstruction, aiming to raise standards in women's health.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will announce its financial results for the quarter ending December 31, 2021, on March 1, 2022, before market opens. The company will host a conference call at 8:30 am ET the same day to discuss these results. Established in 2010, the company focuses on women’s health, particularly breast aesthetics and reconstruction, offering innovative silicone gel-filled Motiva Implants®. Over 2 million of these implants have been distributed across 80 countries, emphasizing its global presence and commitment to advanced healthcare solutions.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported preliminary unaudited revenue for Q4 2021 expected between
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global leader in women's health technology, has announced that CEO Juan José Chacón-Quirós will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 1:30 PM ET. A live webcast of the presentation will be available on the company's investor relations website, with an archived version accessible afterward. Establishment Labs specializes in breast aesthetics and reconstruction, offering innovative Motiva Implants with over 1.8 million units delivered since 2010 across 80 countries.
Establishment Labs (NASDAQ: ESTA) has appointed Raj Denhoy as Chief Financial Officer, effective immediately. Denhoy, who joined the company in February 2021 and served as Interim CFO since August, has extensive experience in medical device research. CEO Juan José Chacón-Quirós highlighted Denhoy's understanding of the business and industry vision. Denhoy expressed optimism about the company's potential to lead in breast aesthetics and reconstruction, emphasizing innovation and stakeholder value.
Establishment Labs Holdings (NASDAQ: ESTA) announced the immediate appointment of Leslie Gillin to its Board of Directors, bringing extensive experience in consumer marketing and finance. CEO Juan José Chacón-Quirós expressed confidence in Gillin's ability to enhance patient engagement and innovative business models. Gillin, formerly of JPMorgan Chase and Citibank, aims to leverage the company’s unique technologies for improved patient experiences and expanded market presence. Established in 2010, Establishment Labs focuses on breast health with over 1.8 million Motiva Implants® sold globally.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced participation in the Stephens Annual Investment Conference from December 1-3, 2021. CEO Juan José Chacón-Quirós and Interim CFO Raj Denhoy will speak on December 2 at 1:00 pm CT. The presentation will be available via live webcast on the company's investor relations website, with an archived version accessible post-event. Establishment Labs focuses on women's health, providing innovative breast aesthetics solutions, including its Motiva Implants, with over 1.8 million units delivered since 2010.
FAQ
What is the current stock price of Establishment Labs Holdings (ESTA)?
What is the market cap of Establishment Labs Holdings (ESTA)?
What does Establishment Labs Holdings Inc. specialize in?
What is the flagship product of Establishment Labs?
In which regions does Establishment Labs operate?
How does Establishment Labs distribute its products?
What are the recent achievements of Establishment Labs?
What is the focus of Establishment Labs' ongoing projects?
How long has Establishment Labs been in the breast implant manufacturing industry?
What sets Motiva Implants® apart from other products in the market?
Is Establishment Labs a publicly traded company?